Mater Private Hospital, Dublin, Ireland.
Ophthalmologica. 2010;224(5):283-90. doi: 10.1159/000299179. Epub 2010 Mar 24.
To determine the efficacy and safety of Artisan phakic intraocular lenses (IOLs) for refractive error correction.
A prospective study was conducted on patients undergoing Artisan phakic IOL implantation for myopia, hyperopia or astigmatism from 2002 to 2008. Visual acuity, manifest refractive spherical equivalent (MRSE), endothelial cell counts and higher order aberrations were recorded pre- and postoperatively.
One hundred and fifty-one (84 patients) myopic (mean MRSE -11.2 +/- 4.1 D) and 14 (7 patients) hyperopic eyes (mean MRSE 7.1 +/- 1.3 D) were treated. Twenty eyes (11 patients) had toric IOLs to correct astigmatism (mean MRSE -9.05 +/- 6.13 D, mean astigmatism 4.06 +/- 1.26 D). Three months postoperatively, mean MRSE in 37.6% of eyes was within +/-0.5 D, 61.8% within +/-1.0 D and 91.4% within +/-2.0 D. 18.5% underwent keratorefractive surgery to correct residual refractive error. A 1.56-fold increase occurred in 4th order spherical aberration. Endothelial cell loss was 1.45% at 1 year and negligible at 5 years. Fifty-four eyes (29.2%) gained one or more lines of best corrected visual acuity and no eye lost a line.
Artisan phakic IOLs are safe and effective for refractive error correction.
评估 Artisan 有晶状体眼人工晶状体（IOL）矫正屈光不正的疗效和安全性。
前瞻性研究 2002 年至 2008 年期间接受 Artisan 有晶状体眼 IOL 植入术矫正近视、远视或散光的患者。记录术前和术后的视力、明显屈光等效球镜（MRSE）、内皮细胞计数和高阶像差。
共治疗 151 只（84 例）近视眼（平均 MRSE-11.2+/-4.1D）和 14 只（7 例）远视眼（平均 MRSE7.1+/-1.3D）。20 只眼（11 例）使用散光 IOL 矫正散光（平均 MRSE-9.05+/-6.13D，平均散光 4.06+/-1.26D）。术后 3 个月，37.6%的眼平均 MRSE 在+/-0.5D 以内，61.8%在+/-1.0D 以内，91.4%在+/-2.0D 以内。18.5%的患者行角膜屈光手术矫正残余屈光不正。第 4 阶球差增加 1.56 倍。内皮细胞丢失率在 1 年时为 1.45%，5 年时可忽略不计。54 只眼（29.2%）获得 1 行或多行最佳矫正视力，无一行视力下降。
Artisan 有晶状体眼 IOL 矫正屈光不正安全有效。
